Aurobindo Pharma Q3 net drops 18% to ₹491 crore
1 year, 10 months ago

Aurobindo Pharma Q3 net drops 18% to ₹491 crore

The Hindu  

Drugmaker Aurobindo Pharma’s consolidated net profit declined more than 18%, year-on-year, in the December quarter to ₹491 crore even as revenue from operations increased 6.7% to ₹6,407.1 crore. Revenue from formulations were 9.2% more at ₹5,452.5 crore on the back of an increase in the same range in the U.S market to ₹3,001.2 crore. Vice-Chairman and MD K. Nithyananda Reddy said “we witnessed an improved momentum backed by recovery across our business verticals and our endeavour is to continuously innovate and differentiate.” He said the aim is to sustain the momentum with new launches, improved cost efficiencies and adherence to the highest standards of compliance supported by strong execution. Aurobindo Pharma has declared an interim dividend of ₹3 per equity share of ₹1 each.

491 Crore  net  momentum  innovate  formulations  q3  aurobindo  pharma  revenue  dividend  company  increased  improved  drops  interim  18  491  crore

History of this topic

Natco Pharma net profit rises 59% in June quarter to ₹669 crore
4 months, 1 week ago

Natco Pharma net profit rises 59% in June quarter to ₹669 crore

The Hindu  

Natco Pharma reported consolidated net profit rose 59% in the June quarter to ₹668.50 crore from ₹420.3 crore in the year-earlier period on the back of robust formulation exports. The higher net profit came on a 21.60% increase in the total revenue to ₹1,410.70 crore for the quarter. Segmental revenue split provided in a release by Natco showed formulation exports …

Aurobindo Pharma Q1 Results: Net profit rises 61.3% to ₹918 crore, revenue up 10.5% YoY
4 months, 2 weeks ago

Aurobindo Pharma Q1 Results: Net profit rises 61.3% to ₹918 crore, revenue up 10.5% YoY

Live Mint  

Aurobindo Pharma Q1 Results: Aurobindo Pharma released its April-June quarter results for fiscal 2024-25 on August 10, reporting a rise of 61.3 per cent in net profit at ₹918 crore, compared to ₹569 crore in the corresponding period last year. The pharma major's revenue from operations during the first quarter of current fiscal stood at ₹7,567 crore, registering a rise …

Large cap stock hits 52-week high after US FDA conducts inspection at subsidiary
1 year ago

Large cap stock hits 52-week high after US FDA conducts inspection at subsidiary

Live Mint  

Shares of Aurobindo Pharma were locked in at over four per cent upper circuit at ₹1,081.45 apiece on the BSE, hitting its new 52-week high mark on Wednesday, December 20. ‘’The US FDA had conducted an inspection at the Unit IV, a Formulation manufacturing facility, of APL Healthcare Limited, a wholly owned subsidiary of the Company, situated at Menakuru Village, …

Aurobindo Pharma share price rises more than 1% on regulatory clearance of plant
1 year, 1 month ago

Aurobindo Pharma share price rises more than 1% on regulatory clearance of plant

Live Mint  

The news on the successful Completion of US FDA Inspection at Unit I & III of Aurobindo Pharma Ltd lifted investor sentiments and the share prices gained of Aurobindo Pharma gained more than 1% in morning trades on Monday, on a day when benchmark indices were trading in red. Aurobindo Pharma in its filing on the exchanges said that United …

Dividend stocks: Anupam Rasayan, Aurobindo Pharma, Cochin Shipyard, 7 other shares to trade ex-dividend today
1 year, 1 month ago

Dividend stocks: Anupam Rasayan, Aurobindo Pharma, Cochin Shipyard, 7 other shares to trade ex-dividend today

Live Mint  

The board of directors of these companies have declared an interim dividend, bonus issues, and buyback of shares for its eligible shareholders. Dividend stocks in November 2023 Anupam Rasayan India has declared an interim dividend of ₹0.50 per share, Aurobindo Pharma has declared an interim dividend of ₹3 per share, Balrampur Chini Mills has declared an interim dividend of ₹3 …

Aurobindo shares double on US show
1 year, 4 months ago

Aurobindo shares double on US show

Live Mint  

Aurobindo Pharma Ltd saw its stock prices more than double during the last few months, from 52-week lows of ₹397.20 on the National Stock Exchange on 3 February to 52-week highs of ₹887.70 on 14 August. The European operations, which is the second largest contributor to the company’s overall revenues and contribute more than a fourth to them, are expected …

Pharma stock approves interim dividend at 450%, record date next week
2 years, 6 months ago

Pharma stock approves interim dividend at 450%, record date next week

Live Mint  

While announcing its Q4FY22 earnings, drug firm Aurobindo Pharma said its board has recommended fourth interim dividend of 450% i.e ₹4.50 per equity share of Re 1/- each on the equity share capital of the company for the financial year 2021-22. The company has already fixed the record date for the purpose of payment of fourth interim dividend for the …

Bank of India, Aurobindo Pharma, Bata India: Top stocks for Investors Today
3 years, 10 months ago

Bank of India, Aurobindo Pharma, Bata India: Top stocks for Investors Today

News 18  

The stock market on Wednesday, February 10, closed in the red for the second consecutive day and witnessed volatility throughout the session. Top stocks to look for the day are: Bank of India: The public sector lender in its quarterly earnings report said that its net profit rose by 412 percent to Rs 541 crore in the December Quarter compared …

Aurobindo Pharma shares surge on Q2 earnings
4 years, 1 month ago

Aurobindo Pharma shares surge on Q2 earnings

Live Mint  

Shares of Aurobindo Pharma surged as much as 7% today after the company reported a 26% increase in consolidated net profit in the second quarter ended September. Aurobindo Pharma on Wednesday reported a 26% increase in consolidated net profit at ₹805.65 crore in the second quarter ended September. The company had posted a consolidated net profit of ₹639.53 crore in …

Aurobindo Eyes 40% Rise in US Injectables Business in FY18
7 years, 1 month ago

Aurobindo Eyes 40% Rise in US Injectables Business in FY18

Live Mint  

Aurobindo Pharma's US injectables business is expected to grow at least 40% this financial year, driven by new launches and higher sales from existing products. The company's injectables business has been growing significantly over the last two-three years, with US injectable sales rising by 67% in FY16-17 and 39% in FY15-16. The company expects about seven to nine product approvals …

Discover Related